Consolidation with high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compared with intensive standard-dose chemotherapy alone

Biology of Blood and Marrow Transplantation

Volumn 12, Issue 2, 2006, Pages 195-203

  Vredenburgh, James J ^a   Coniglio, David ^a   Broadwater, Gloria ^a   Jones, Roy B ^b   Ross, Maureen ^c   Shpall, Elizabeth J ^b   Hussein, Atif ^d   Rizzieri, David ^a   Marks, Larry B ^a   Gilbert, Colleen ^e   Affronti, Mary Lou ^a   Moore, Sarah ^a   McDonald, Carolyn ^a   Petros, William P ^f   Peters, William P ^a,g  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d Memorial Regional Trauma Center   (United States)

^e Critical Thinking Co   (United States)

^f WEST VIRGINIA UNIVERSITY   (United States)

^g Adherex Technologies Inc   (United States)

Author keywords

Bone marrow transplantation; High dose chemotherapy; Hormone insensitive metastatic breast cancer; Intensive induction chemotherapy

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; METHOTREXATE;

ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BACTERIAL INFECTION; BLEEDING; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; HEMOLYTIC UREMIC SYNDROME; HUMAN; INFLAMMATORY DISEASE; INTERSTITIAL PNEUMONIA; LIVER METASTASIS; LUNG METASTASIS; LUNG TOXICITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTIPLE ORGAN FAILURE; MYCOSIS; PLEURA METASTASIS; RANDOMIZED CONTROLLED TRIAL; SALVAGE THERAPY; SKIN TOXICITY; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE; VEIN OCCLUSION; VIRUS INFECTION; VISCERAL METASTASIS;

ADULT; ALKYLATING AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION; S100 PROTEINS; SALVAGE THERAPY; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS;

EID: 31344459870     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2005.10.009     Document Type: Article

References (30)

1. A. Jemal T. Murray A. Samuels A. Ghafoor E. Ward M.J. Thun Cancer statistics, 2003 CA Cancer J Clin 55 2003 5-26
2. M.E. Costanza R.B. Weiss I.C. Henderson et al. Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: Report of a randomized study - Cancer and Leukemia Group B 8642 J Clin Oncol 17 1999 1397-1406
3. Z.U. Rahman D.K. Frye T.L. Smith et al. Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy: A reference Cancer 85 1999 104-111
4. R. Paridaens L. Biganzoli P. Bruning et al. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: A European Organization for Research and Treatment of Cancer randomized study with cross-over J Clin Oncol 18 2000 724-733
5. D. Loesch N. Robert L. Asmar et al. Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer J Clin Oncol 20 2002 3857-3864
6. G.M. Clark G.W. Sledge Jr C.K. Osborne W.L. McGuire Survival from first recurrence: Relative importance of prognostic factors in 1,015 breast cancer patients J Clin Oncol 5 1987 55-61
7. G. Falkson R.S. Gelman L. Leone C.I. Falkson Survival of premenopausal women with metastatic breast cancer: Long-term follow-up of Eastern Cooperative Group and Cancer and Leukemia Group studies Cancer 66 1990 1621-1629
8. J.A. Sparano P. Hu R.M. Rao C.I. Falkson A.C. Wolff W.C. Wood Phase II trial of doxorubicin and paclitaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: An Eastern Cooperative Oncology Group Study J Clin Oncol 17 1999 3828-3834
9. K. Antman L. Ayash A. Elias et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy J Clin Oncol 10 1992 102-110
10. G.F. Laport G. Grad D.L. Grinblatt J.D. Bitran S.F. Williams High-dose chemotherapy consolidation with autologous stem cell rescue in metastatic breast cancer: A 10-year experience Bone Marrow Transplant 21 1998 127-132
11. F. Dunphy G. Spitzer J. Fornoff et al. Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support Cancer 73 1994 2157-2167
12. L. Ayash C. Wheeler D. Fairclough et al. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer J Clin Oncol 13 1995 2043-2049
13. L.T. Vahdat C. Balmaceda K. Papadopoulos et al. Phase II trial of sequential high-dose chemotherapy with paclitaxel, melphalan and cyclophosphamide, thiotepa and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer Bone Marrow Transplant 30 2002 149-155
14. Z.U. Rahman D.K. Frye A.U. Buzdar et al. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer J Clin Oncol 15 1997 3171-3177
15. R.B. Jones E.J. Shpall J. Shogan et al. The Duke AFM Program: Intensive induction chemotherapy for metastatic breast cancer Cancer 66 1990 431-436
16. W.P. Peters M. Ross J.J. Vredenburgh et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer J Clin Oncol 11 1993 1132-1143
17. W.P. Peters G. Rosner M. Ross et al. Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy Blood 81 1993 1709-1719
18. J.P. Eder K. Antman W.P. Peters et al. High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer J Clin Oncol 4 1986 1592-1597
19. D.L. Carter L.B. Marks J.M. Bean et al. Impact of consolidation radiotherapy in patients with advanced breast cancer treated with high-dose chemotherapy and autologous bone marrow rescue J Clin Oncol 17 1999 887-894
20. E.L. Kaplan P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457-481
21. R. Peto M.C. Pike P. Armitage et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient Br J Cancer 31 1977 7-9
22. D.A. Rizzieri J.J. Vredenburgh R. Jones et al. Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support J Clin Oncol 17 1999 3064-3074
23. H.G. Sayer K. Schilling T. Vogt et al. Double high-dose chemotherapy with adriamycin, paclitaxel, cyclophosphamide, and thiotepa followed by autologous peripheral blood stem cell transplantation in women with metastatic breast cancer J Cancer Res Clin Oncol 129 2003 361-366
24. G. Somolo W. Chow V. Hamasaki et al. Tandem-cycle high-dose melphalan and cisplatin with peripheral blood progenitor cell support in patients with breast cancer and other malignancies Biol Blood Marrow Transplant 7 2001 284-293
25. P.A.C. Greenberg G.N. Hortobagyi T.L. Smith L.D. Ziegler D.K. Frye A.U. Buzdar Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer J Clin Oncol 14 1996 2197-2205
26. J. O'Shaughnessy D. Miles S. Vukelja et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results J Clin Oncol 20 2002 2812-2823
27. E.A. Stadtmauer A. O'Neill L.J. Goldstein et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer N Engl J Med 342 2000 1069-1076
28. D. Berry G. Broadwater J. Klein et al. High-dose versus standard chemotherapy in metastatic breast cancer: Comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry J Clin Oncol 20 2002 743-750
29. P. Pedrazzoli P. Ferrante A. Kulecki et al. Autologous hematopoietic stem cell transplantation for breast cancer in Europe: Critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990-1999 Bone Marrow Transplant 32 2003 489-494
30. A.D. Elias J. Ibrahim P. Richardson et al. The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: An analysis of sequential phase I/II trials from the Dana-Farber/Beth Israel STAMP program Biol Blood Marrow Transplant 8 2002 198-205